Open Access

Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre 18F-FDG PET/CT and bone marrow biopsy evaluation study

Andrej Doma
Andrej Doma
, 
Katarina Zevnik
Katarina Zevnik
, 
Andrej Studen
Andrej Studen
, 
Veronika Kloboves Prevodnik
Veronika Kloboves Prevodnik
, 
Gorana Gasljevic
Gorana Gasljevic
 and 
Barbara Jezersek Novakovic
Barbara Jezersek Novakovic
   | Feb 21, 2024
Radiology and Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: Feb 21, 2024
Page range: 15 - 22
Received: Oct 15, 2023
Accepted: Jan 03, 2024
DOI: https://doi.org/10.2478/raon-2024-0004
Keywords
© 2024 Andrej Doma et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

Overall survival.
Overall survival.

FIGURE 2.

Gender based survival analysis.
Gender based survival analysis.

FIGURE 3.

International prognostic index (IPI) survival analysis.HR = high risk; HIR = high-intermediate risk; LIR = low-intermediate risk; LR = low risk
International prognostic index (IPI) survival analysis.HR = high risk; HIR = high-intermediate risk; LIR = low-intermediate risk; LR = low risk

FIGURE 4.

Bone marrow involvement status survival analysis.BM = bone marrow
Bone marrow involvement status survival analysis.BM = bone marrow

The six-colour antibody panel used for flow-cytometric immunophenotyping of bone marrow (BM) aspirates

Tube FITC PE PerCP-Cy5,5 APC PE-Cy7 APC-Cy7
1. mAb κ λ CD19 CD5 CD10 CD45
Vé 5 μl 5 μl 5 μl 3 μl 2 μl 3 μl
2. mAb CD34 CD117 CD33 HLA-DR CD14 CD45
Vé 3 μl 3 μl 2 μl 2 μl 3 μl 3 μl
3. mAb CD3 CD56 CD5 CD20 CD19 CD45
Vé 1 μl 3 μl 3 μl 6 μl 3 μl 3 μl
4. mAb CD19 CD45
Vé 5 μl 3 μl
5. mAb FMC7 CD23 CD19 CD5 CD10 CD45
Vé 6 μl 6 μl 5 μl 3μl
6. mAb CD52 CD11c CD19 CD38 CD45
Vé 3 μl 5 μl 5 μl 3 μl 3 μl
7. mAb CD103 CD22 CD19 CD25 CD45
Vé 5 μl 4 μl 5 μl 2 μl 3 μl
8. mAb CD38 CD56 CD19 CD138 CD45
Vé 5 μl 3 μl 5 μl 5 μl 3 μl
9. mAb CD4 CD8 CD3 CD7 CD5 CD45
Vé 3 μl 4 μl 3 μl 2 μl 5 μl 3 μl

Patients’ characteristics

Age (median, range), years 65 (20–79)
Gender, female/male, n (%) 64 (44.1%)/81 (55.9%)
BMI − BMI +
Age (median) [years]; BMI−: BMI+ 66 (25–79) 63(20–78); p = 0.524
Gender, female/male, n; 48/54 16/27; p = 0.277
IPI score, n (%)
IPI Low risk group (LR): 33 (22.8%) 32 1
IPI Low-intermediate risk group (LIR): 32 (22.1%) 22 10
IPI High-intermediate risk group (HIR): 33 (22.8%) 24 9
IPI High risk group (HR): 47 (32.4%) 24 23
Stage at diagnosis, n (%) II: 39 (26.9%)
III: 19 (13.1%)
IV: 87 (60.0%)
Chemotherapy regimen, n (%) R-CHOP: 119 (82.1%)
R-EPOCH: 9 (6.2%)
R-ACVBP: 6 (4.1%)
RCOEP: 3 (2.1%)
Other: 8 (5.5%)
Radiotherapy after chemotherapy, n (%) 52 (35.9%)
Death in 60 months follow-up period, n (%) 29 (20.0%)
Bone marrow involvements present-overall, n (%) 43 (29.7%)
Extranodal sites: 0, n (%) 26 (17.9%)
Extranodal sites: 1, n (%) 48 (33.1%); of those BMI n = 11 (7.6%)
Extranodal sites more than 1, no. (%) 71 (49.0%)
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed